

Warren Casey, PhD, DABT
NTP Interagency Center for the Evaluation of Alternative
Toxicological Methods (NICEATM)
National Institute of Environmental Health Sciences

NTP Board of Scientific Counselors Meeting June 15 – 16, 2016






## February 17-18, 2016

US EPA, RTP, NC

Emphasis on utilization of HTS data and compatible approaches



# In Vitro to In Vivo Extrapolation for High Throughput Prioritization and Decision Making



#### WORKSHOP

Wednesday, February 17, 2016 • 8:00 a.m. – 6:00 p.m. Thursday, February 18, 2016 • 8:30 a.m. – 3:00 p.m.

> U.S. Environmental Protection Agency Research Triangle Park, North Carolina

For agenda and registration information, visit http://ntp.niehs.nih.gov/go/ivive-wksp-2016

Individuals with disabilities who need accommodation to participate in this event should contact Elizabeth Moull at 919-316-4668 or manillyniebrank gov. TTY users should contact the Federal TTY Rolay Service at 800-877-8339. Requests should be made at least Sourises also in advance of the event.

Any individual seeding access to the EPA campus will need to be prepared to show a photo ID (a.g., driver's license, or a company, government, or university ID) and provide either a copy of this flyer or pertinent information about the seminar (e.g., name of the seeds), but or of the of the seminar.







## In Vitro - In Vivo Extrapolation (IVIVE)

Utilization of *in vitro* data and *in silico* approaches to predict phenomena in vivo

- Toxicokinetics (TK)
  - Fate of molecules/chemicals in body
  - Considers absorption, distribution, metabolism, excretion (ADME)
- Toxicodynamics (TD)
  - In vivo effect of chemicals interacting with a biological target



## In Vitro - In Vivo Extrapolation (IVIVE)

Utilization of *in vitro* data and *in silico* approaches to predict phenomena in vivo

- Toxicokinetics (TK)
  - Fate of molecules/chemicals in body
  - Considers absorption, distribution, metabolism, excretion (ADME)
- Toxicodynamics (TD)
  - In vivo effect of chemicals interacting with a biological target



## **Toxicokinetics (TK)**

Provides a bridge between toxicity and exposure assessment by predicting tissue concentrations resulting from a given exposure


- Traditional TK methods are resource intensive
- Relatively high throughput TK (HTTK) methods have been used by the pharmaceutical industry to determine range of efficacious doses and to prospectively evaluate success of planned clinical trials (Jamei, et al., 2009; Wang, 2010)
- Reverse Toxicokinetics (RTK) is key component of IVIVE



## Reverse ToxicoKinetics (RTK)

 Estimate daily doses that produce plasma concentrations equivalent to the bioactive concentrations identified by HTS assays






Chem Concentration (blood/tissue)









Chem Concentration (culture medium)





Chem Concentration (culture medium)








Minimum dose that would be expected to cause serum levels high enough to interact with

**Receptor X** 


**Dose** (in vivo)





Potential Hazard

**Dose** (in vivo)






**Potential** 

**Exposure** 

## **IVIVE Workshop**






## **Example Using ToxCast/Tox21 Data**

Pharmacokinetics allows context for high throughput screening data






ToxCast
Bioactivity
Converted to
mg/kg/day
with HTTK
(Wetmore et
al., 2012)

ExpoCast Exposure Predictions (Wambaugh et al., 2014)

**ToxCast Chemicals** 





AC 50, Receptor X (culture medium)


Hepatocytes or Microsomes?



**Dose** (in vivo)

One compartment or PBPK? Which parameters? What assumptions?

Which methodology/protocol? Rat or Human? QSAR (which one)?



AC 50, Receptor X (culture medium)

AC50 or POD / other?
Nominal or estimated available?

Hepatocytes or Microsomes? Which methodology/protocol? Rat or Human? Male and Female? QSAR (which one)?




#### Goals

For using IVIVE in risk assessment and prioritization:

- Review state of the science
- Discuss best practices
- Identify data gaps



In Vitro to In Vivo
Extrapolation for
High Throughput
Prioritization
and Decision Making



#### WORKSHOP

Wednesday, February 17, 2016 • 8:00 a.m. – 6:00 p.m. Thursday, February 18, 2016 • 8:30 a.m. – 3:00 p.m.

> U.S. Environmental Protection Agency Research Triangle Park, North Carolina

For agenda and registration information, visit http://ntp.niehs.nih.gov/go/ivive-wksp-2016

Individuals with disabilities who need accommodation to participate in this event should contact Elizabeth Mauli at 919-316-4668 or mauligniehschlagor. TIY users should contact the Federal TIY Relay Service at 800-877-8339. Requests should be made at least 5 business day in advance of the event.

Any individual seeking access to the EPA campus will need to be prepared to show a photo ID (e.g., driver's license, or a company, government, or university ID) and provide either a copy of this flyer or pertinent information about the seminar (e.g., name of the speaker, host, or title of the seminar).







## **Pre-Workshop Webinar Series**

- Average attendance ~130 participants, ~400 registered
- Provided background in preparation for the in person workshop
- Face to face participants felt webinars strongly contributed to the in person meeting

**October 7:** Setting the Stage: Purpose, Definitions, Scope, and Assumptions *Barbara Wetmore, Ph.D., ScitoVation* 

**November 4:** Building Fit-for-purpose Pharmacokinetic Models *John Wambaugh, Ph.D., U.S.* 

**December 3:** The Role of Pharmacokinetic Model Evaluation *Lisa Sweeney, Ph.D., Naval Medical* 

January 6: Framework for Establishing an Internal Threshold of Toxicological Concern

Corie Ellison, Ph.D., The Procter &



## Workshop

- Two-days followed 3 themes
  - Toxicokinetic (TK) model considerations
  - In silico and non-animal methods for obtaining TK parameters
  - Application to prioritization/screening/risk assessment


- Ten speakers from industry, academia, and government

Roughly 100 participants



### **Outcomes**

- Characterization of chemical space used to create computational models
  - Much of our information is based on pharmaceuticals
  - Review article exploring how the chemical space impacts models and interpretation





#### **Outcomes**


- Database for in vitro and in vivo PK/TK data and models
  - Guidelines for documentation of data and models
  - Efforts underway to collate data, develop common ontology, and host database with web interface, EPA/NTP



#### **Outcomes**

- Workshop Report Manuscript
  - Request by the speakers/organizing committee to push up the submission for workshop manuscript due to its relevance
  - Will included recommended best practices and discussion of variability/uncertainty associated with each key model parameter
  - Publication to be submitted to Toxicology In Vitro this fall





Webinar and Workshop materials available online @ <a href="http://ntp.niehs.nih.gov/go/ivive-wksp-2016">http://ntp.niehs.nih.gov/go/ivive-wksp-2016</a>





The horse is out of the barn, these data and models are being used – what are the most necessary refinements and caveats?



John Wambaugh, US EPA



## **IVIVE Workshop Overview**

## **Organizing Committee**

Alicia Paini	EURL ECVAM	Warren Casey	NIEHS/NICEATM
Andrew Worth	EURL ECVAM	Nicole Kleinstreuer	NIEHS/NICEATM
Jos Bessems	EURL ECVAM	Dave Allen	ILS NICEATM
Sandra Coecke	EURL ECVAM	Shannon Bell	ILS NICEATM
		Xiaoqing Chan	ILS NICEATM
Dan Wilson	Dow Chemical Company	Stephen Ferguson	NIEHS/NTP
Justin Teeguarden	Pacific Northwest National Labs	Annie Jarabek	US EPA
John Troutman	The Proctor & Gamble Company	John Wambaugh	US EPA
		Barbara Wetmore	US EPA